Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Entire DC Network
Development Of A Testicular Cancer Vaccine, Roberto Aguilar Iii
Development Of A Testicular Cancer Vaccine, Roberto Aguilar Iii
ETD Archive
Testicular cancer mainly affects men between the ages of 20 and 35 but is the most common male neoplasm between the ages of 15 and 34. The National Cancer Institute (NCI) states that localized testicular cancer has a recurrence rate of 15-20% and tumors that are Sertoli or Leydig cell derived fail to respond to chemotherapy or radiation treatments. The recurrence rate may increase to 32% if at diagnosis the tumor is greater than 4 cm in size with invasion of the rete testes. To improve therapy for testicular cancer, we examined the usefulness of a testicular cancer vaccine. We …